WIN-Partners Co., Ltd.

Tokyo Stock Exchange 3183.T

WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -9.55 M

WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities is USD -9.55 M for the year ending March 31, 2024, a -9.08% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD -8.75 M, a 16.52% change year over year.
WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -10.48 M, a -22.56% change year over year.
WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -8.55 M, a -0.14% change year over year.
WIN-Partners Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -8.54 M, a -13.77% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Tokyo Stock Exchange: 3183.T

WIN-Partners Co., Ltd.

CEO	Mr. Hideumi Akizawa
IPO Date	Sept. 16, 2002
Location	Japan
Headquarters	Kyobashi Edogrand
Employees	629
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Hardware & Electronics

Description

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring and magnetic resonance imaging equipment. The company was founded in 1973 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years